Study of Efficacy and Safety of TL-FVP-t vs. SOC in Patients With Mild to Moderate COVID-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

168 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-05-20

Study Completion Date

2020-08-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Randomized open-label multicenter parallel-group study of efficacy and safety of TL-FVP-t vs. standard of care therapy in patients with mild to moderate coronavirus disease (SARS-CoV-2/COVID-19)

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19

NCT04542694

COVID-19

COMPLETED PHASE3

Randomized Multicenter Study on the Efficacy and Safety of Favipiravir for Parenteral Administration Compared to Standard of Care in Hospitalized Patients With COVID-19

NCT05185284

COVID-19

COMPLETED PHASE3

Study of the Use of Favipiravir in Hospitalized Subjects With COVID-19

NCT04358549

COVID-19

COMPLETED PHASE2

Philippine Trial to Determine Efficacy and Safety of Favipiravir for COVID-19

NCT05014373

Covid19

UNKNOWN PHASE3

Oral Favipiravir Compared to Placebo in Subjects With Mild COVID-19

NCT04346628

Sars-CoV2 COVID-19

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This was an open label, randomized, controlled, multicenter Phase 3 study of TL-FVP-t in outpatients and inpatients with mild to moderate COVID-19. After stratification by the severity of their disease (mild or moderate), age (18-44 or ≥ 45 years) and CT severity subjects were randomized at a rate of 2:1 to receive either TL-FVP-t + standard concomitant therapy or standard ethiptropic therapy (standard of care - SOC) including standard concomitant therapy. Standard ethiptropic therapy according to MoH of Russian Federation included umifenovir + intranasal recombinant interferon alpha, hydroxichloroquine, or chloroquine.

The dose regimen was the following: TL-FVP-t at a dose of 1800 mg BID on the Day 1 followed by 800 mg BID during the next 9 days. The study included the period of therapy (10 days) and follow-up period (18 days).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

TL-FVP-t (favipiravir) Treatment Arm

Day 1: favipiravir 1800 mg BID plus Standard of Care (SOC); Days 2-10: 800 mg BID plus SOC.

Group Type EXPERIMENTAL

Favipiravir

Intervention Type DRUG

TL-FVP-t will be administered orally

standard concomitant therapy

Intervention Type DRUG

Standard of care according to MoH of Russian Federation recomendation for COVID-19

Standard of Care Arm

Standard of Care including etiotropic therapy according to MoH of Russian Federation Recomendations for COVID-19 (umifenovir + intranasal recombinant interferon alpha, or hydroxychloroquine, or chloroquine, or mefloquine in recomended regimen) up to10 days

Group Type ACTIVE_COMPARATOR

Standard of care (SOC)

Intervention Type DRUG

SOC will include standard etiotropic therapy (umifenovir + intranasal recombinant interferon alpha, or hydroxychloroquine, or chloroquine) according to MoH of Russian Federation recomendations for COVID-19

standard concomitant therapy

Intervention Type DRUG

Standard of care according to MoH of Russian Federation recomendation for COVID-19

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Favipiravir

TL-FVP-t will be administered orally

Intervention Type DRUG

Standard of care (SOC)

SOC will include standard etiotropic therapy (umifenovir + intranasal recombinant interferon alpha, or hydroxychloroquine, or chloroquine) according to MoH of Russian Federation recomendations for COVID-19

Intervention Type DRUG

standard concomitant therapy

Standard of care according to MoH of Russian Federation recomendation for COVID-19

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

TL-FVP-t Koronavir

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Informed consent form signed.
2. Males and females aged 18-60 years;
3. Diagnosis of coronavirus disease caused by SARS-CoV-2 (COVID-19) in a mild or moderate form (without respiratory failure).
4. Duration of infection symptoms shall be no more than 6 days before randomization.
5. SARS-CoV-2 infection should be verified by PCR at the screening.
6. Ability to follow the protocol and fulfill all the clinical study procedures.
7. Ability and willingness of the subjects and their sexual partners with retained childbearing potential to use reliable contraception methods throughout the study and for 3 months after the treatment completion.
8. Willingness not to take alcohol throughout the study.

Exclusion Criteria

1. Age \< 18 and \> 60 years.
2. Any etiotropic therapy of coronavirus SARS-CoV-2 (COVID-19) infection prior to the study.
3. Moderate infection with respiratory failure, severe or extremely severe SARS-CoV-2 (COVID-19) disease.
4. Respiratory failure (RR \> 30/min, SpO2 ≤ 93 %) or the need for mechanical ventilation at the screening.
5. Decreased level of consciousness (disorientation of place, time and personality), agitation at the screening.
6. Unstable hemodynamics (systolic BP \< 100 mm Hg or diastolic BP \< 60 mm Hg) found at the screening.
7. Subtotal diffuse ground-glass induration of pulmonary tissue and pulmonary consolidation combined with reticular changes; involvement of ≥ 75 % of lung parenchyma; hydrothorax (CT findings corresponding to ≥ CT-4 according to Department of Health of Moscow guidelines).
8. Presence of comorbidities:

1. moderate or severe chronic obstructive pulmonary disease or asthma;
2. severe chronic cardiovascular disorders (arrhythmia or conduction disorders, implanted pacemaker device, myocardial infarction or unstable angina in the medical history, heart failure);
3. immunocompromised subjects (HIV, cancer, autoimmune diseases, immunodepressant therapy);
4. severe obesity (body mass index \[BMI\] ≥ 40);
5. diabetes mellitus;
6. chronic renal failure;
7. chronic moderate or severe hepatic disorders.
9. Any of the following abnormal laboratory tests at the screening: AST or ALT level \> 2.5 x upper normal level (UNL), platelet count \< 50х109/L.
10. Any history findings which, in the investigator's opinion, may complicate the interpretation of the study results or generate an additional risk for the subject due to his/her participation in the study.
11. More than 2 CT diagnostic procedures within the last 6 months prior to randomization (except for chest CT no earlier than 4 days prior to enrollment).
12. The subject takes the products significantly inhibiting CYP28С, and administration those products cannot be interrupted for the study duration.
13. Malabsorption syndrome or another clinically relevant gastrointestinal disease which may affect the study product absorption (uncontrollable vomiting, diarrhea, ulcerative colitis, etc.).
14. Pregnancy or breast-feeding; women with probable pregnancy at the screening, those planning to conceive during the study.
15. Known (from the history) or suspected alcohol or psychotropic drug abuse; medicinal or illicit drug addiction.
16. Mental disorders including those in the medical history.
17. Condition or disease which, according to the investigator or medical monitor, will compromise the subject's safety or affect assessment of the study product safety.

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No